| 0 (0%) | 09-27 09:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.68 | 1-year : | 21.82 |
| Resists | First : | 16 | Second : | 18.68 |
| Pivot price | 10.44 |
|||
| Supports | First : | 7.17 | Second : | 1.72 |
| MAs | MA(5) : | 10.6 | MA(20) : | 11.01 |
| MA(100) : | 7.29  |
MA(250) : | 7.78 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 78.3 |
D(3) : | 77.9 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 28.19 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EIGR ] has closed above bottom band by 45.5%. Bollinger Bands are 99.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.02 - 10.07 | 10.07 - 10.11 |
| Low: | 9.85 - 9.92 | 9.92 - 9.97 |
| Close: | 9.9 - 10.01 | 10.01 - 10.09 |
Fri, 16 Aug 2024
Document - SEC.gov
Mon, 01 Apr 2024
Peninsula biotech files for Chapter 11 bankruptcy protection - The Business Journals
Thu, 09 Nov 2023
Eiger BioPharma: Q3 Earnings Snapshot - qz.com
Tue, 12 Sep 2023
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta - PR Newswire
Mon, 14 Aug 2023
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - PR Newswire
Thu, 13 Apr 2023
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 11.8 (%) |
| Held by Institutions | 43.8 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 42 (K) |
| EPS | -58.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.09 |
| Profit Margin | 0 % |
| Operating Margin | -527.6 % |
| Return on Assets (ttm) | -52.5 % |
| Return on Equity (ttm) | -226 % |
| Qtrly Rev. Growth | -20.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.91 |
| EBITDA (p.s.) | -56.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | -9.26 |
| Price to Sales | 1 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|